5ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAIDUse:A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents[J].JAHA,2008,118(18):1894-1909.
4Serebruany VL,Steinhubi SR,Berger PB,et al.Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.Am J Cardio1,2005,95:1218-1222.
5Walker J,Robinson J,Stewart J,et al.Does enteric-ccated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact Cardiovasc Thorac Stag,2007,6:519-522.
6Kelly JP,Kanfman DW,Jurgelon JM,et al.Risk of aspirinassociated major upper-gastrointestinal bleeding with enteric-coated or buffered product.Lancet,1996,348:1413-1416.
7Hemandez-Diaz S,Garcia Rodriguez LA.Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications.BMC Med,2006,4:22.
8Taha AS,Angerson WJ,Prnsad R,et al.Clinical trial:the incidence and early mortality after peptic ulcer perforation,and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs.Aliment Pharmacol Ther,2008,28:878-885.
9Papatheodoridis GV,Sougioultzis S,Archimandrifis AJ.Effcts of Helicobacter pylori and nonsteroidal anti-inflammatery drugs on peptic ulcer disease:a systematic review.Clin Gastroenterol Hepatol,2006,4:130-142.
10Huang JQ,Sridhar S,Hunt RH.Role of Helicobacter pylori infection and non-steroidal anti-infammatury drugs in peptic-ulcer disease:a meta-analysis.Lancet,2002,359:14-22.
